Aesthetic practitioner Dr Alex Parys is set to host a talk as part of the Northwest Emergency Medicine Regional Training Day taking place at North Manchester General Hospital on December 19.
The Food and Drug Administration (FDA) has approved AKLIEF (trifarotene) Cream 0.005% for the topical treatment of acne.
Global pharmaceutical company Galderma’s liquid formulation of botulinum toxin type A has achieved positive results for the treatment of glabellar lines in a phase 2 clinical trial.
Global pharmaceutical company Allergan has received US Food and Drug Administration (FDA) approval for the use of Juvéderm VOLUMA XC with a TSK STERiGLIDE cannula for cheek augmentation to correct age-related volume definition in the mid-face in adults over 21.
On September 4, the fourth Academic Aesthetics Mastermind Group was hosted by co-owners of Trikwan Aesthetics clinic Dr Zoya Diwan and Dr Sanjay Trikha in Mayfair.
A study has suggested that retrobulbar hyaluronidase injection is unlikely to alleviate vision loss caused by hyaluronic acid (HA) filler injections.
US hair loss technology provider Kerastem has confirmed that patients who underwent the Phase 2 clinical trial in early-stage hair loss achieved an increase in mean terminal hair count in men with early hair loss when compared to the control group. Based on these results, Kerastem plans to begin a Phase 3 clinical trial later this year.
The Food and Drug Administration (FDA) has approved Jeuveau, a botulinum toxin type A, for the temporary improvement in the appearance of moderate to severe glabellar lines.
A recent BBC Panorama programme has highlighted the need for stricter regulations around the use of medical devices in the healthcare sector.
Practitioners from Indonesia travelled to London especially for a workshop held by Dalvi Humzah Aesthetic Training (DHAT) at the Royal Society of Medicine, London.